A first-in-human study of transjugular transcatheter tricuspid valve replacement with the LuX-Valve Plus system

DOI: 10.4244/EIJ-D-22-00517

Yuan Zhang
Yuan Zhang1, MD; Fanglin Lu2, MD; Wei Li1, MB; Shasha Chen1, MD; Mingfei Li1, MD; Xiaochun Zhang1, MB; Cuizhen Pan1, MB; Fan Qiao2, MD; Daxin Zhou1, MD; Wenzhi Pan1, MD; Junbo Ge1, MD
1. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China; 2. Department of Cardiovascular Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China
Introduction Transcatheter tricuspid valve replacement (TTVR) is now a promising option for tricuspid regurgitation (TR) patients at high risk for surgery. The LuX-Valve (Jenscare Biotechnology) is a radial force-independent orthotopic TTVR device. The feasibility and efficacy of this device have been reported by several studies123. However, this valve was implanted through right atrial access, where a small incision of the right chest and right atrium is needed. The LuX-Valve Plus valve replacement system is the second-generation version of the LuX-Valve and can be implanted through the jugular vein. The aim of the study was to report the first-in-human results of ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
A large, prospective, multicentre study of left main PCI using a latest-generation zotarolimus-eluting stent: the ROLEX study

Latest news